GALT

+ Watchlist + Portfolio

Galectin Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.67
52-Week Range: $2.03 – $7.13
Market Cap: $360.03M
P/E (TTM): —
EPS (TTM): -0.43
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: -36.15
Return on Equity: —
Return on Assets: -64.18%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.10
Debt/Equity: —
Total Debt: $143.96M
Free Cash Flow: $-14.86M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $494.94M

GALT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$31.74M	$32.13M	$36.57M	$14.29M
Selling, General & Admin	$6.62M	$5.94M	$5.86M	$5.79M
Operating Expenses	$38.35M	$38.07M	$42.43M	$20.09M
Operating Income	-$38.35M	-$38.07M	-$42.43M	-$20.09M
EBITDA	-$37.71M	-$38.24M	-$41.47M	-$23.45M
Pretax Income	-$38.78M	-$41.07M	-$47.05M	-$30.84M
Net Income	-$38.78M	-$41.07M	-$47.05M	-$30.84M
Diluted EPS	-0.65	-0.74	-0.76	-0.48
Diluted Shares	59.39M	60.16M	62.31M	63.90M

GALT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.59M	$25.66M	$15.12M	$17.72M
Current Assets	$20.55M	$27.71M	$17.25M	$19.44M
Total Assets	$21.29M	$28.20M	$17.50M	$19.53M
Current Liabilities	$13.01M	$15.68M	$35.41M	$8.03M
Long-Term Debt	$39.83M	$71.74M	$85.11M	$133.74M
Total Debt	$39.87M	$71.79M	$106.25M	$133.76M
Total Liabilities	$53.48M	$88.44M	$120.56M	$145.73M
Retained Earnings	-$309.57M	-$354.37M	-$401.57M	-$432.55M
Shareholders' Equity	-$32.19M	-$60.24M	-$103.07M	-$126.19M
Working Capital	$7.54M	$12.03M	-$18.16M	$11.41M
Net Debt	$21.24M	$46.08M	$91.11M	$116.02M

GALT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$31.06M	-$32.97M	-$41.77M	-$23.88M
Free Cash Flow	-$31.06M	-$32.97M	-$41.77M	-$23.88M
Depreciation & Amortisation	$32.00K	$33.00K	$37.00K	$53.00K
Stock-Based Compensation	$2.87M	$2.26M	$2.45M	$1.66M
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$10.00M	$40.03M	$31.23M	$26.48M
Net Change in Cash	-$21.06M	$7.07M	-$10.54M	$2.60M

GALT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.49M	$3.26M	$2.61M	$1.93M	$2.23M
Selling, General & Admin	$1.41M	$1.36M	$1.59M	$1.43M	$1.85M
Operating Expenses	$7.90M	$4.63M	$4.20M	$3.37M	$4.08M
Operating Income	-$7.90M	-$4.63M	-$4.20M	-$3.37M	-$4.08M
EBITDA	-$7.88M	-$5.69M	-$6.36M	-$3.52M	-$3.05M
Pretax Income	-$9.63M	-$7.52M	-$8.18M	-$5.50M	-$5.05M
Net Income	-$9.63M	-$7.52M	-$8.18M	-$5.50M	-$5.05M
Diluted EPS	-0.15	-0.12	-0.13	—	-0.08
Diluted Shares	63.20M	63.45M	64.20M	—	65.78M

GALT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$7.43M	$13.77M	$11.53M	$17.72M	$14.11M
Current Assets	$9.29M	$15.43M	$12.73M	$19.44M	$15.69M
Total Assets	$9.53M	$15.60M	$12.87M	$19.53M	$15.76M
Current Liabilities	$110.84M	$10.77M	$136.44M	$8.03M	$7.31M
Long-Term Debt	$10.81M	$120.46M	—	$133.74M	$135.71M
Total Debt	$107.99M	$120.51M	$122.31M	$133.76M	$135.72M
Total Liabilities	$121.79M	$132.77M	$138.17M	$145.73M	$146.00M
Retained Earnings	-$411.18M	-$418.76M	-$426.98M	-$432.55M	-$437.61M
Shareholders' Equity	-$112.26M	-$117.17M	-$125.30M	-$126.19M	-$130.24M
Working Capital	-$101.56M	$4.65M	-$123.72M	$11.41M	$8.38M
Net Debt	$100.49M	$106.69M	$110.75M	$116.02M	$121.60M

GALT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.69M	-$6.60M	-$3.54M	-$6.04M	-$3.87M
Free Cash Flow	-$7.69M	-$6.60M	-$3.54M	-$6.04M	-$3.87M
Depreciation & Amortisation	$10.00K	$2.00K	$0.00	$41.00K	$12.00K
Stock-Based Compensation	$468.00K	$500.00K	$496.00K	$195.00K	$686.00K
Financing Cash Flow	$0.00	$12.94M	$1.30M	$12.24M	$257.00K
Net Change in Cash	-$7.69M	$6.34M	-$2.25M	$6.20M	-$3.61M

Market Snapshot

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing therapies for the treatment of fibrotic liver disease and cancer. The company's lead drug candidate, belapectin, is a galectin-3 inhibitor being evaluated in clinical trials for cirrhosis and nonalcoholic steatohepatitis (NASH) with advanced fibrosis. Galectin Therapeutics is also exploring applications in cancer treatment, where galectin-3 plays a role in tumor progression and metastasis. The company is headquartered in Norcross, Georgia, and focuses on addressing significant unmet medical needs in liver diseases.